# VeraMorph gets NIH grant for breast cancer drug

> Pharmaceutical startup VeraMorph secures $2.1M NIH grant to develop oral breast cancer treatment.
- Title: VeraMorph gets NIH grant for breast cancer drug · Dealroom
- Summary: Pharmaceutical startup VeraMorph secures $2.1M NIH grant to develop oral breast cancer treatment. VeraMorph, a specialty pharmaceutical startup, received a…
- Keywords: veramorph, nih, breast cancer, fulvestrant, oral drug, metastatic breast cancer, sbir phase ii, ind enabling, startups, business, gets, grant
- Source: Dealroom — https://dealroom.co/news/163727-veramorph-lands-2-1m-nih-grant-taps-ex-eagle-executive-as-ceo
- Published: 2026-10-19T01:28:11+00:00
- Read time: 1 min
- Topics: veramorph, nih, breast cancer, fulvestrant, oral drug, metastatic breast cancer, sbir phase ii, ind enabling, startups, business
## Grant secured
VeraMorph, a specialty pharmaceutical startup, received a $2.1 million SBIR Phase II grant from the National Institutes of Health to fund IND-enabling work on its oral formulation of fulvestrant.
## New CEO appointed
Daniel O'Connor, former chief strategy officer of Eagle Pharmaceuticals, was named chief executive officer to lead the company's clinical strategy.
## Drug development timeline
The company targets clinical entry in 2027 and an NDA filing in 2029 after completing preclinical studies with the grant funds.
## Key takeaway

VeraMorph, a specialty pharmaceutical startup, received a $2.1 million NIH grant to fund preclinical work on an oral fulvestrant formulation for metastatic breast cancer.